LK
Lawrence Otto Klein
Chief Executive OfficerDirector

Lawrence Otto Klein insider trades: Oruka Therapeutics (ORKA) stock sales

Chief Executive Officer, Oruka Therapeutics Last trade Nov 2, 2026 36 Form 4 filings
$11.8M
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2019
5
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Lawrence reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 2, 2026ORKA↓ Sell$2.4M
Oct 1, 2026ORKA↓ Sell$2.1M
Sep 15, 2026ORKA↓ Sell$235K
Sep 1, 2026ORKA↓ Sell$6.9M
Jun 15, 2026ORKA↓ Sell$120K
Mar 16, 2026ORKA↓ Sell$71K
Mar 23, 2021CRSP↓ Sell$12.8M
Jan 15, 2021CRSP↓ Sell$5.4M
Jun 25, 2020CRSP↓ Sell$5.3M
May 11, 2020CRSP↓ Sell$1.5M
Jul 11, 2019CRSP↓ Sell$1.0M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ORKA insiders

Open-market trades in the last 12 months

About Lawrence Otto Klein's insider trades

Lawrence Otto Klein is Chief Executive Officer at Oruka Therapeutics (ORKA). Since Jul 11, 2019, Lawrence has reported no open-market purchases and 11 sales worth $37.8M on SEC Form 4. In the last 12 months: 6 sales ($11.8M).

Their filings also include grants and awards (21 filings), option exercises (12 filings), shares withheld for taxes (5 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ORKA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.